ID   SL9A1_HUMAN             Reviewed;         815 AA.
AC   P19634; B1ALD6; D3DPL4; Q96EM2;
DT   01-FEB-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1991, sequence version 2.
DT   10-MAY-2017, entry version 188.
DE   RecName: Full=Sodium/hydrogen exchanger 1;
DE   AltName: Full=APNH;
DE   AltName: Full=Na(+)/H(+) antiporter, amiloride-sensitive;
DE   AltName: Full=Na(+)/H(+) exchanger 1;
DE            Short=NHE-1;
DE   AltName: Full=Solute carrier family 9 member 1;
GN   Name=SLC9A1; Synonyms=APNH1, NHE1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=2536298; DOI=10.1016/0092-8674(89)90901-X;
RA   Sardet C., Franchi A., Pouyssegur J.;
RT   "Molecular cloning, primary structure, and expression of the human
RT   growth factor-activatable Na+/H+ antiporter.";
RL   Cell 56:271-280(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Kidney;
RX   PubMed=2154036; DOI=10.1126/science.2154036;
RA   Sardet C., Counillon L., Franchi A., Pouyssegur J.;
RT   "Growth factors induce phosphorylation of the Na+/H+ antiporter,
RT   glycoprotein of 110 kD.";
RL   Science 247:723-726(1990).
RN   [3]
RP   SEQUENCE REVISION.
RX   PubMed=1712287;
RA   Tse C.-M., Ma A.I., Yang V.W., Watson A.J.M., Levine S.,
RA   Montrose M.H., Potter J., Sardet C., Pouyssegur J., Donowitz M.;
RT   "Molecular cloning and expression of a cDNA encoding the rabbit ileal
RT   villus cell basolateral membrane Na+/H+ exchanger.";
RL   EMBO J. 10:1957-1967(1991).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Heart;
RX   PubMed=8283968; DOI=10.1007/BF00936442;
RA   Fliegel L., Dyck J.R., Wang H., Fong C., Haworth R.S.;
RT   "Cloning and analysis of the human myocardial Na+/H+ exchanger.";
RL   Mol. Cell. Biochem. 125:137-143(1993).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10913675; DOI=10.1016/S0165-4608(99)00246-0;
RA   Garden O.A., Musk P., Worthington-White D.A., Dewey M.J., Rich I.N.;
RT   "Silent polymorphisms within the coding region of human
RT   sodium/hydrogen exchanger isoform-1 cDNA in peripheral blood
RT   mononuclear cells of leukemia patients: a comparison with healthy
RT   controls.";
RL   Cancer Genet. Cytogenet. 120:37-43(2000).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   GLYCOSYLATION AT ASN-75, AND O-LINKED GLYCOSYLATION.
RX   PubMed=8068684; DOI=10.1021/bi00200a030;
RA   Counillon L., Pouyssegur J., Reithmeier R.A.;
RT   "The Na+/H+ exchanger NHE-1 possesses N- and O-linked glycosylation
RT   restricted to the first N-terminal extracellular domain.";
RL   Biochemistry 33:10463-10469(1994).
RN   [10]
RP   INTERACTION WITH CHP1.
RX   PubMed=8967452;
RA   Goss G., Orlowski J., Grinstein S.;
RT   "Coimmunoprecipitation of a 24-kDa protein with NHE1, the ubiquitous
RT   isoform of the Na+/H+ exchanger.";
RL   Am. J. Physiol. 270:C1493-C1502(1996).
RN   [11]
RP   FUNCTION IN PH REGULATION, AND INTERACTION WITH CHP1.
RX   PubMed=8901634; DOI=10.1073/pnas.93.22.12631;
RA   Lin X., Barber D.L.;
RT   "A calcineurin homologous protein inhibits GTPase-stimulated Na-H
RT   exchange.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:12631-12636(1996).
RN   [12]
RP   TOPOLOGY.
RX   PubMed=9688597;
RA   Shrode L.D., Gan B.S., D'Souza S.J., Orlowski J., Grinstein S.;
RT   "Topological analysis of NHE1, the ubiquitous Na+/H+ exchanger using
RT   chymotryptic cleavage.";
RL   Am. J. Physiol. 275:C431-C439(1998).
RN   [13]
RP   TOPOLOGY, AND MUTAGENESIS OF ARG-180 AND GLN-181.
RX   PubMed=10713111; DOI=10.1074/jbc.275.11.7942;
RA   Wakabayashi S., Pang T., Su X., Shigekawa M.;
RT   "A novel topology model of the human Na(+)/H(+) exchanger isoform 1.";
RL   J. Biol. Chem. 275:7942-7949(2000).
RN   [14]
RP   INTERACTION WITH TESC, AND SUBCELLULAR LOCATION.
RX   PubMed=11696366; DOI=10.1016/S0014-5793(01)02986-6;
RA   Mailaender J., Mueller-Esterl W., Dedio J.;
RT   "Human homolog of mouse tescalcin associates with Na(+)/H(+) exchanger
RT   type-1.";
RL   FEBS Lett. 507:331-335(2001).
RN   [15]
RP   FUNCTION, INTERACTION WITH CHP1, AND MUTAGENESIS OF ILE-518; ILE-522;
RP   PHE-526; LEU-527; LEU-530; LEU-531 AND 526-PHE--LEU-531.
RX   PubMed=11350981; DOI=10.1074/jbc.M100296200;
RA   Pang T., Su X., Wakabayashi S., Shigekawa M.;
RT   "Calcineurin homologous protein as an essential cofactor for Na+/H+
RT   exchangers.";
RL   J. Biol. Chem. 276:17367-17372(2001).
RN   [16]
RP   INTERACTION WITH CHP2.
RX   PubMed=12226101; DOI=10.1074/jbc.M208313200;
RA   Pang T., Wakabayashi S., Shigekawa M.;
RT   "Expression of calcineurin B homologous protein 2 protects serum
RT   deprivation-induced cell death by serum-independent activation of
RT   Na+/H+ exchanger.";
RL   J. Biol. Chem. 277:43771-43777(2002).
RN   [17]
RP   INTERACTION WITH TESC AND CALMODULIN.
RX   PubMed=12809501; DOI=10.1021/bi027143d;
RA   Li X., Liu Y., Kay C.M., Muller-Esterl W., Fliegel L.;
RT   "The Na+/H+ exchanger cytoplasmic tail: structure, function, and
RT   interactions with tescalcin.";
RL   Biochemistry 42:7448-7456(2003).
RN   [18]
RP   FUNCTION IN PH REGULATION, INTERACTION WITH CHP1, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=15035633; DOI=10.1021/bi0360004;
RA   Pang T., Hisamitsu T., Mori H., Shigekawa M., Wakabayashi S.;
RT   "Role of calcineurin B homologous protein in pH regulation by the
RT   Na+/H+ exchanger 1: tightly bound Ca2+ ions as important structural
RT   elements.";
RL   Biochemistry 43:3628-3636(2004).
RN   [19]
RP   MUTAGENESIS OF PRO-167 AND PRO-168.
RX   PubMed=14680478; DOI=10.1042/BJ20030884;
RA   Slepkov E.R., Chow S., Lemieux M.J., Fliegel L.;
RT   "Proline residues in transmembrane segment IV are critical for
RT   activity, expression and targeting of the Na+/H+ exchanger isoform
RT   1.";
RL   Biochem. J. 379:31-38(2004).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic kidney;
RX   PubMed=17525332; DOI=10.1126/science.1140321;
RA   Matsuoka S., Ballif B.A., Smogorzewska A., McDonald E.R. III,
RA   Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N.,
RA   Lerenthal Y., Shiloh Y., Gygi S.P., Elledge S.J.;
RT   "ATM and ATR substrate analysis reveals extensive protein networks
RT   responsive to DNA damage.";
RL   Science 316:1160-1166(2007).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-703, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-697; SER-703; SER-723;
RP   SER-726; SER-729 AND SER-785, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [23]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-703, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-703, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   INTERACTION WITH CHP2, AND SUBCELLULAR LOCATION.
RX   PubMed=21392185; DOI=10.1111/j.1365-2443.2011.01497.x;
RA   Li Q.H., Wang L.H., Lin Y.N., Chang G.Q., Li H.W., Jin W.N., Hu R.H.,
RA   Pang T.X.;
RT   "Nuclear accumulation of calcineurin B homologous protein 2 (CHP2)
RT   results in enhanced proliferation of tumor cells.";
RL   Genes Cells 16:416-426(2011).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-703, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [27]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-602; SER-605; SER-693;
RP   SER-703 AND SER-785, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-599; SER-602 AND
RP   SER-703, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [29]
RP   INVOLVEMENT IN LIKNS, VARIANT LIKNS ARG-305, AND CHARACTERIZATION OF
RP   VARIANT LIKNS ARG-305.
RX   PubMed=25205112; DOI=10.1093/hmg/ddu461;
RA   Guissart C., Li X., Leheup B., Drouot N., Montaut-Verient B.,
RA   Raffo E., Jonveaux P., Roux A.F., Claustres M., Fliegel L., Koenig M.;
RT   "Mutation of SLC9A1, encoding the major Na[?]/H[?] exchanger, causes
RT   ataxia-deafness Lichtenstein-Knorr syndrome.";
RL   Hum. Mol. Genet. 24:463-470(2015).
RN   [30]
RP   STRUCTURE BY NMR OF 155-180, AND MUTAGENESIS OF PHE-155; LEU-156;
RP   GLN-157; SER-158; ASP-159; VAL-160; PHE-161; PHE-162; LEU-163;
RP   PHE-164; LEU-165; LEU-166; PRO-167; PRO-168; ILE-169; ILE-170;
RP   LEU-171; ASP-172; ALA-173; GLY-174; TYR-175; PHE-176 AND LEU-177.
RX   PubMed=15677483; DOI=10.1074/jbc.M409608200;
RA   Slepkov E.R., Rainey J.K., Li X., Liu Y., Cheng F.J., Lindhout D.A.,
RA   Sykes B.D., Fliegel L.;
RT   "Structural and functional characterization of transmembrane segment
RT   IV of the NHE1 isoform of the Na+/H+ exchanger.";
RL   J. Biol. Chem. 280:17863-17872(2005).
RN   [31]
RP   PRELIMINARY X-RAY CRYSTALLOGRAPHY OF 503-545 IN COMPLEX WITH CHP2.
RX   PubMed=16511206; DOI=10.1107/S1744309105030836;
RA   Ben Ammar Y., Takeda S., Sugawara M., Miyano M., Mori H.,
RA   Wakabayashi S.;
RT   "Crystallization and preliminary crystallographic analysis of the
RT   human calcineurin homologous protein CHP2 bound to the cytoplasmic
RT   region of the Na+/H+ exchanger NHE1.";
RL   Acta Crystallogr. F 61:956-958(2005).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.7 ANGSTROMS) OF 503-545 IN COMPLEX WITH CHP2,
RP   AND MUTAGENESIS OF ILE-534 AND ILE-537.
RX   PubMed=16710297; DOI=10.1038/sj.emboj.7601145;
RA   Ammar Y.B., Takeda S., Hisamitsu T., Mori H., Wakabayashi S.;
RT   "Crystal structure of CHP2 complexed with NHE1-cytosolic region and an
RT   implication for pH regulation.";
RL   EMBO J. 25:2315-2325(2006).
RN   [33]
RP   STRUCTURE BY NMR OF 503-545 IN COMPLEX WITH CHP1.
RX   PubMed=17050540; DOI=10.1074/jbc.M604092200;
RA   Mishima M., Wakabayashi S., Kojima C.;
RT   "Solution structure of the cytoplasmic region of Na+/H+ exchanger 1
RT   complexed with essential cofactor calcineurin B homologous protein
RT   1.";
RL   J. Biol. Chem. 282:2741-2751(2007).
CC   -!- FUNCTION: Involved in pH regulation to eliminate acids generated
CC       by active metabolism or to counter adverse environmental
CC       conditions. Major proton extruding system driven by the inward
CC       sodium ion chemical gradient. Plays an important role in signal
CC       transduction. {ECO:0000269|PubMed:11350981,
CC       ECO:0000269|PubMed:15035633, ECO:0000269|PubMed:8901634}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Fully active at acidic pHs, the antiporter is virtually turned
CC         off at neutral pH.;
CC   -!- SUBUNIT: Oligomer (By similarity). Interacts with calmodulin and
CC       TESC. Interacts (via the juxtamembrane region of the cytoplasmic
CC       C-terminal domain) with CHP1; the interaction occurs at the plasma
CC       membrane in a calcium-dependent manner. Interacts with CHP2; the
CC       interaction occurs in a calcium-dependent manner. {ECO:0000250,
CC       ECO:0000269|PubMed:11350981, ECO:0000269|PubMed:11696366,
CC       ECO:0000269|PubMed:12226101, ECO:0000269|PubMed:12809501,
CC       ECO:0000269|PubMed:15035633, ECO:0000269|PubMed:16710297,
CC       ECO:0000269|PubMed:17050540, ECO:0000269|PubMed:21392185,
CC       ECO:0000269|PubMed:8901634, ECO:0000269|PubMed:8967452}.
CC   -!- SUBCELLULAR LOCATION: Membrane; Multi-pass membrane protein.
CC       Endoplasmic reticulum membrane {ECO:0000250}; Multi-pass membrane
CC       protein {ECO:0000250}. Cell membrane; Multi-pass membrane protein.
CC       Note=Colocalizes with CHP1 at the reticulum endoplasmic (By
CC       similarity). Colocalizes with CHP1 and CHP2 at the plasma
CC       membrane. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=P19634-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P19634-2; Sequence=VSP_022101, VSP_022102;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Kidney and intestine.
CC   -!- PTM: O-glycosylated. {ECO:0000269|PubMed:8068684}.
CC   -!- PTM: Ubiquitinated, leading to its degradation by the proteasome.
CC       Ubiquitination is reduced by CHP1 (By similarity). {ECO:0000250}.
CC   -!- DISEASE: Lichtenstein-Knorr syndrome (LIKNS) [MIM:616291]: An
CC       autosomal recessive neurologic disorder characterized by
CC       progressive cerebellar ataxia and severe progressive sensorineural
CC       hearing loss. {ECO:0000269|PubMed:25205112}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- MISCELLANEOUS: Inhibited by amiloride and 5-amino-substituted
CC       derivatives and activated in a cooperative fashion by
CC       intracellular H(+). In quiescent cells upon growth factor
CC       stimulation, the apparent affinity for internal H(+) is increased,
CC       resulting in a persistent rise in cytoplasmic pH.
CC   -!- SIMILARITY: Belongs to the monovalent cation:proton antiporter 1
CC       (CPA1) transporter (TC 2.A.36) family. {ECO:0000305}.
CC   -!- CAUTION: The region between transmembrane regions M4 and M5 and
CC       between M6 and M7 (also termed intracellular loops IL2 and IL4,
CC       respectively) seem to be localized at least in part in the
CC       membrane. The hydrophobic region H10 is proposed to be located
CC       within the membrane. {ECO:0000305}.
CC   -!- CAUTION: Although PubMed:12809501 report that TESC-binding results
CC       in a decrease in activity, studies with rat SLC9A1 show that TESC-
CC       binding results in the maturation and accumulation of SLC9A1 at
CC       the cell surface. {ECO:0000305}.
CC   -!- CAUTION: Although PubMed:12809501 report that CHP1 and TESC bind
CC       to SLC9A1 at different sites, studies with rat SLC9A1 show that
CC       they bind at the same C-terminal site. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M81768; AAB59460.1; ALT_SEQ; mRNA.
DR   EMBL; S68616; AAC60606.1; -; mRNA.
DR   EMBL; AF141350; AAF21350.1; -; mRNA.
DR   EMBL; AF141351; AAF21351.1; -; mRNA.
DR   EMBL; AF141352; AAF21352.1; -; mRNA.
DR   EMBL; AF141353; AAF21353.1; -; mRNA.
DR   EMBL; AF141354; AAF21354.1; -; mRNA.
DR   EMBL; AF141355; AAF21355.1; -; mRNA.
DR   EMBL; AF141356; AAF21356.1; -; mRNA.
DR   EMBL; AF141357; AAF21357.1; -; mRNA.
DR   EMBL; AF141358; AAF21358.1; -; mRNA.
DR   EMBL; AF141359; AAF21359.1; -; mRNA.
DR   EMBL; AF146430; AAF25592.1; -; mRNA.
DR   EMBL; AF146431; AAF25593.1; -; mRNA.
DR   EMBL; AF146432; AAF25594.1; -; mRNA.
DR   EMBL; AF146433; AAF25595.1; -; mRNA.
DR   EMBL; AF146434; AAF25596.1; -; mRNA.
DR   EMBL; AF146435; AAF25597.1; -; mRNA.
DR   EMBL; AF146436; AAF25598.1; -; mRNA.
DR   EMBL; AF146437; AAF25599.1; -; mRNA.
DR   EMBL; AF146438; AAF25600.1; -; mRNA.
DR   EMBL; AF146439; AAF25601.1; -; mRNA.
DR   EMBL; AL590640; CAH73555.1; -; Genomic_DNA.
DR   EMBL; AL137860; CAH73555.1; JOINED; Genomic_DNA.
DR   EMBL; AL590640; CAH73556.1; -; Genomic_DNA.
DR   EMBL; AL137860; CAH73556.1; JOINED; Genomic_DNA.
DR   EMBL; AL137860; CAI22089.1; -; Genomic_DNA.
DR   EMBL; AL590640; CAI22089.1; JOINED; Genomic_DNA.
DR   EMBL; AL137860; CAI22090.1; -; Genomic_DNA.
DR   EMBL; AL590640; CAI22090.1; JOINED; Genomic_DNA.
DR   EMBL; CH471059; EAX07773.1; -; Genomic_DNA.
DR   EMBL; CH471059; EAX07774.1; -; Genomic_DNA.
DR   EMBL; BC012121; AAH12121.1; -; mRNA.
DR   CCDS; CCDS295.1; -. [P19634-1]
DR   PIR; I57487; I57487.
DR   RefSeq; NP_003038.2; NM_003047.4. [P19634-1]
DR   UniGene; Hs.469116; -.
DR   PDB; 1Y4E; NMR; -; A=155-180.
DR   PDB; 2BEC; X-ray; 2.70 A; B=503-545.
DR   PDB; 2E30; NMR; -; B=503-545.
DR   PDB; 2HTG; NMR; -; A=250-274.
DR   PDB; 2KBV; NMR; -; A=447-472.
DR   PDB; 2L0E; NMR; -; A=226-250.
DR   PDB; 2MDF; NMR; -; A=226-274.
DR   PDB; 2YGG; X-ray; 2.23 A; A=622-689.
DR   PDBsum; 1Y4E; -.
DR   PDBsum; 2BEC; -.
DR   PDBsum; 2E30; -.
DR   PDBsum; 2HTG; -.
DR   PDBsum; 2KBV; -.
DR   PDBsum; 2L0E; -.
DR   PDBsum; 2MDF; -.
DR   PDBsum; 2YGG; -.
DR   ProteinModelPortal; P19634; -.
DR   SMR; P19634; -.
DR   BioGrid; 112438; 37.
DR   IntAct; P19634; 13.
DR   MINT; MINT-194742; -.
DR   STRING; 9606.ENSP00000263980; -.
DR   BindingDB; P19634; -.
DR   ChEMBL; CHEMBL2781; -.
DR   DrugBank; DB00594; Amiloride.
DR   DrugBank; DB02624; Homoserine Lactone.
DR   TCDB; 2.A.36.1.13; the monovalent cation:proton antiporter-1 (cpa1) family.
DR   iPTMnet; P19634; -.
DR   PhosphoSitePlus; P19634; -.
DR   BioMuta; SLC9A1; -.
DR   DMDM; 127809; -.
DR   EPD; P19634; -.
DR   MaxQB; P19634; -.
DR   PaxDb; P19634; -.
DR   PeptideAtlas; P19634; -.
DR   PRIDE; P19634; -.
DR   Ensembl; ENST00000263980; ENSP00000263980; ENSG00000090020. [P19634-1]
DR   Ensembl; ENST00000374086; ENSP00000363199; ENSG00000090020. [P19634-2]
DR   GeneID; 6548; -.
DR   KEGG; hsa:6548; -.
DR   UCSC; uc001bnm.5; human. [P19634-1]
DR   CTD; 6548; -.
DR   DisGeNET; 6548; -.
DR   GeneCards; SLC9A1; -.
DR   HGNC; HGNC:11071; SLC9A1.
DR   HPA; CAB022371; -.
DR   HPA; HPA048532; -.
DR   HPA; HPA052891; -.
DR   MalaCards; SLC9A1; -.
DR   MIM; 107310; gene.
DR   MIM; 616291; phenotype.
DR   neXtProt; NX_P19634; -.
DR   OpenTargets; ENSG00000090020; -.
DR   PharmGKB; PA35928; -.
DR   eggNOG; KOG1966; Eukaryota.
DR   eggNOG; COG0025; LUCA.
DR   GeneTree; ENSGT00760000119074; -.
DR   HOGENOM; HOG000247044; -.
DR   HOVERGEN; HBG052615; -.
DR   InParanoid; P19634; -.
DR   KO; K05742; -.
DR   OMA; KPIMIST; -.
DR   OrthoDB; EOG091G02Q0; -.
DR   PhylomeDB; P19634; -.
DR   TreeFam; TF317212; -.
DR   Reactome; R-HSA-2160916; Hyaluronan uptake and degradation.
DR   Reactome; R-HSA-425986; Sodium/Proton exchangers.
DR   SignaLink; P19634; -.
DR   SIGNOR; P19634; -.
DR   ChiTaRS; SLC9A1; human.
DR   EvolutionaryTrace; P19634; -.
DR   GeneWiki; Sodium%E2%80%93hydrogen_antiporter_1; -.
DR   GenomeRNAi; 6548; -.
DR   PRO; PR:P19634; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000090020; -.
DR   CleanEx; HS_SLC9A1; -.
DR   ExpressionAtlas; P19634; baseline and differential.
DR   Genevisible; P19634; HS.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0016323; C:basolateral plasma membrane; IEA:Ensembl.
DR   GO; GO:0090533; C:cation-transporting ATPase complex; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; IDA:UniProtKB.
DR   GO; GO:0016021; C:integral component of membrane; TAS:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:BHF-UCL.
DR   GO; GO:0014704; C:intercalated disc; IEA:Ensembl.
DR   GO; GO:0030027; C:lamellipodium; TAS:BHF-UCL.
DR   GO; GO:0045121; C:membrane raft; IDA:BHF-UCL.
DR   GO; GO:0005739; C:mitochondrion; IEA:Ensembl.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0030315; C:T-tubule; IEA:Ensembl.
DR   GO; GO:0048306; F:calcium-dependent protein binding; IDA:UniProtKB.
DR   GO; GO:0005516; F:calmodulin binding; IEA:UniProtKB-KW.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; TAS:BHF-UCL.
DR   GO; GO:0015386; F:potassium:proton antiporter activity; IBA:GO_Central.
DR   GO; GO:0030674; F:protein binding, bridging; TAS:BHF-UCL.
DR   GO; GO:0032947; F:protein complex scaffold; TAS:BHF-UCL.
DR   GO; GO:0030346; F:protein phosphatase 2B binding; IDA:BHF-UCL.
DR   GO; GO:0015385; F:sodium:proton antiporter activity; IDA:UniProtKB.
DR   GO; GO:0086040; F:sodium:proton antiporter activity involved in regulation of cardiac muscle cell membrane potential; TAS:BHF-UCL.
DR   GO; GO:0015299; F:solute:proton antiporter activity; TAS:UniProtKB.
DR   GO; GO:0086003; P:cardiac muscle cell contraction; IEA:Ensembl.
DR   GO; GO:0055007; P:cardiac muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0016049; P:cell growth; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; TAS:BHF-UCL.
DR   GO; GO:0071468; P:cellular response to acidic pH; IDA:BHF-UCL.
DR   GO; GO:0071236; P:cellular response to antibiotic; IEA:Ensembl.
DR   GO; GO:0071257; P:cellular response to electrical stimulus; IEA:Ensembl.
DR   GO; GO:0071872; P:cellular response to epinephrine stimulus; IMP:BHF-UCL.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; TAS:BHF-UCL.
DR   GO; GO:0006883; P:cellular sodium ion homeostasis; IDA:BHF-UCL.
DR   GO; GO:0030214; P:hyaluronan catabolic process; TAS:Reactome.
DR   GO; GO:1902600; P:hydrogen ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:0006811; P:ion transport; TAS:Reactome.
DR   GO; GO:0030011; P:maintenance of cell polarity; TAS:BHF-UCL.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0070997; P:neuron death; IEA:Ensembl.
DR   GO; GO:0045760; P:positive regulation of action potential; IEA:Ensembl.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IEA:Ensembl.
DR   GO; GO:0070886; P:positive regulation of calcineurin-NFAT signaling cascade; IDA:BHF-UCL.
DR   GO; GO:1903281; P:positive regulation of calcium:sodium antiporter activity; IMP:BHF-UCL.
DR   GO; GO:0010613; P:positive regulation of cardiac muscle hypertrophy; IMP:BHF-UCL.
DR   GO; GO:0030307; P:positive regulation of cell growth; IEA:Ensembl.
DR   GO; GO:0035794; P:positive regulation of mitochondrial membrane permeability; IEA:Ensembl.
DR   GO; GO:0051533; P:positive regulation of NFAT protein import into nucleus; IDA:BHF-UCL.
DR   GO; GO:0098735; P:positive regulation of the force of heart contraction; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription from RNA polymerase II promoter; IDA:BHF-UCL.
DR   GO; GO:0071805; P:potassium ion transmembrane transport; IBA:GO_Central.
DR   GO; GO:0051259; P:protein oligomerization; ISS:UniProtKB.
DR   GO; GO:0086036; P:regulation of cardiac muscle cell membrane potential; TAS:BHF-UCL.
DR   GO; GO:0010882; P:regulation of cardiac muscle contraction by calcium ion signaling; IMP:BHF-UCL.
DR   GO; GO:0051893; P:regulation of focal adhesion assembly; TAS:BHF-UCL.
DR   GO; GO:0051453; P:regulation of intracellular pH; IDA:UniProtKB.
DR   GO; GO:0006885; P:regulation of pH; IDA:UniProtKB.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; TAS:BHF-UCL.
DR   GO; GO:0086092; P:regulation of the force of heart contraction by cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:0010447; P:response to acidic pH; IDA:UniProtKB.
DR   GO; GO:0042493; P:response to drug; IEA:Ensembl.
DR   GO; GO:0035994; P:response to muscle stretch; IMP:BHF-UCL.
DR   GO; GO:0071436; P:sodium ion export; ISS:UniProtKB.
DR   GO; GO:0098719; P:sodium ion import across plasma membrane; IDA:BHF-UCL.
DR   InterPro; IPR006153; Cation/H_exchanger.
DR   InterPro; IPR018422; Cation/H_exchanger_CPA1.
DR   InterPro; IPR001970; Na/H_exchanger_1.
DR   InterPro; IPR004709; NaH_exchanger.
DR   InterPro; IPR032103; NHE_CaM-bd.
DR   PANTHER; PTHR10110; PTHR10110; 1.
DR   PANTHER; PTHR10110:SF143; PTHR10110:SF143; 1.
DR   Pfam; PF00999; Na_H_Exchanger; 1.
DR   Pfam; PF16644; NEXCaM_BD; 1.
DR   PRINTS; PR01084; NAHEXCHNGR.
DR   PRINTS; PR01085; NAHEXCHNGR1.
DR   TIGRFAMs; TIGR00840; b_cpa1; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Antiport; Calmodulin-binding;
KW   Cell membrane; Complete proteome; Deafness; Disease mutation;
KW   Endoplasmic reticulum; Glycoprotein; Ion transport; Membrane;
KW   Neurodegeneration; Phosphoprotein; Polymorphism; Reference proteome;
KW   Sodium; Sodium transport; Transmembrane; Transmembrane helix;
KW   Transport; Ubl conjugation.
FT   CHAIN         1    815       Sodium/hydrogen exchanger 1.
FT                                /FTId=PRO_0000052347.
FT   TOPO_DOM      1     12       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     13     33       Helical; Name=M1. {ECO:0000255}.
FT   TOPO_DOM     34    105       Extracellular. {ECO:0000255}.
FT   TRANSMEM    106    127       Helical; Name=M2. {ECO:0000255}.
FT   TOPO_DOM    128    129       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    130    149       Helical; Name=M3. {ECO:0000255}.
FT   TOPO_DOM    150    154       Extracellular. {ECO:0000255}.
FT   TRANSMEM    155    174       Helical; Name=M4. {ECO:0000255}.
FT   TOPO_DOM    175    191       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    192    211       Helical; Name=M5. {ECO:0000255}.
FT   TOPO_DOM    212    227       Extracellular. {ECO:0000255}.
FT   TRANSMEM    228    247       Helical; Name=M6. {ECO:0000255}.
FT   TOPO_DOM    248    256       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    257    276       Helical; Name=M7. {ECO:0000255}.
FT   TOPO_DOM    277    294       Extracellular. {ECO:0000255}.
FT   TRANSMEM    295    315       Helical; Name=M8. {ECO:0000255}.
FT   TOPO_DOM    316    338       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    339    358       Helical; Name=M9. {ECO:0000255}.
FT   TOPO_DOM    359    381       Extracellular. {ECO:0000255}.
FT   INTRAMEM    382    402       Name=H10. {ECO:0000250}.
FT   TOPO_DOM    403    410       Extracellular. {ECO:0000255}.
FT   TRANSMEM    411    430       Helical; Name=M10. {ECO:0000255}.
FT   TOPO_DOM    431    448       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    449    470       Helical; Name=M11. {ECO:0000255}.
FT   TOPO_DOM    471    479       Extracellular. {ECO:0000255}.
FT   TRANSMEM    480    499       Helical; Name=M12. {ECO:0000255}.
FT   TOPO_DOM    500    815       Cytoplasmic. {ECO:0000255}.
FT   REGION      516    539       Interaction with CHP2.
FT   SITE        161    161       Channel pore-lining. {ECO:0000305}.
FT   SITE        370    370       Not glycosylated.
FT   MOD_RES     599    599       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     602    602       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     603    603       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q61165}.
FT   MOD_RES     605    605       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     693    693       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     697    697       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     703    703       Phosphoserine.
FT                                {ECO:0000244|PubMed:18088087,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     723    723       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     726    726       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     729    729       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     785    785       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     787    787       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q61165}.
FT   MOD_RES     796    796       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P26431}.
FT   CARBOHYD     75     75       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000269|PubMed:8068684}.
FT   VAR_SEQ     496    554       GMTIRPLVDLLAVKKKQETKRSINEEIHTQFLDHLLTGIED
FT                                ICGHYGHHHWKDKLNRFN -> VLGQGRAGPCLGDPHRLFP
FT                                WKERKACDLKCDSSPSSTTNLLCDLGRATPPFWASVSSIVK
FT                                (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_022101.
FT   VAR_SEQ     555    815       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_022102.
FT   VARIANT     305    305       G -> R (in LIKNS; causes reduced
FT                                expression of the mutant protein;
FT                                hypoglycosylated; does not localize
FT                                properly at the plasma membrane; small
FT                                residual activity; dbSNP:rs786204831).
FT                                {ECO:0000269|PubMed:25205112}.
FT                                /FTId=VAR_073439.
FT   VARIANT     682    682       N -> K (in dbSNP:rs35703140).
FT                                /FTId=VAR_050231.
FT   MUTAGEN     155    155       F->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     156    156       L->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     157    157       Q->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     158    158       S->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     159    159       D->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     160    160       V->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     161    161       F->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     162    162       F->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     163    163       L->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     164    164       F->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     165    165       L->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     166    166       L->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     167    167       P->A: Reduces activity.
FT                                {ECO:0000269|PubMed:14680478,
FT                                ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     167    167       P->C,G: Almost complete loss of activity.
FT                                Reduces membrane localization.
FT                                {ECO:0000269|PubMed:14680478,
FT                                ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     168    168       P->A,C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:14680478,
FT                                ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     168    168       P->G: Reduces activity.
FT                                {ECO:0000269|PubMed:14680478,
FT                                ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     169    169       I->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     170    170       I->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     171    171       L->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     172    172       D->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     173    173       A->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     174    174       G->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     175    175       Y->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     176    176       F->C: Almost complete loss of activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     177    177       L->C: Reduces activity.
FT                                {ECO:0000269|PubMed:15677483}.
FT   MUTAGEN     178    178       P->A: No effect.
FT   MUTAGEN     180    180       R->C: Reduces activity.
FT                                {ECO:0000269|PubMed:10713111}.
FT   MUTAGEN     181    181       Q->C: Reduces activity.
FT                                {ECO:0000269|PubMed:10713111}.
FT   MUTAGEN     518    518       I->Q: Reduces interaction with CHP1 and
FT                                the exchange activity; when associated
FT                                with Q-522.
FT                                {ECO:0000269|PubMed:11350981}.
FT   MUTAGEN     522    522       I->Q: Reduces interaction with CHP1 and
FT                                the exchange activity; when associated
FT                                with Q-518.
FT                                {ECO:0000269|PubMed:11350981}.
FT   MUTAGEN     526    531       FLDHLL->QQDHQQ: Inhibits interaction with
FT                                CHP1 and the exchange activity. CHPI does
FT                                not localize at the cell membrane.
FT                                {ECO:0000269|PubMed:11350981}.
FT   MUTAGEN     526    531       FLDHLL->RRDHRR: Inhibits interaction with
FT                                CHP1 and the exchange activity. CHPI does
FT                                not localize at the cell membrane.
FT                                {ECO:0000269|PubMed:11350981}.
FT   MUTAGEN     526    526       F->Q: Reduces interaction with CHP1 and
FT                                the exchange activity; when associated
FT                                with Q-527.
FT                                {ECO:0000269|PubMed:11350981}.
FT   MUTAGEN     527    527       L->Q: Reduces interaction with CHP1 and
FT                                the exchange activity; when associated
FT                                with Q-526.
FT                                {ECO:0000269|PubMed:11350981}.
FT   MUTAGEN     530    530       L->Q: Reduces interaction with CHP1 and
FT                                the exchange activity; when associated
FT                                with Q-531.
FT                                {ECO:0000269|PubMed:11350981}.
FT   MUTAGEN     531    531       L->Q: Reduces interaction with CHP1 and
FT                                the exchange activity; when associated
FT                                with Q-530.
FT                                {ECO:0000269|PubMed:11350981}.
FT   MUTAGEN     534    534       I->D,K: Strongly reduced interaction with
FT                                CHP2. {ECO:0000269|PubMed:16710297}.
FT   MUTAGEN     537    537       I->K: Strongly reduced interaction with
FT                                CHP2. {ECO:0000269|PubMed:16710297}.
FT   HELIX       162    165       {ECO:0000244|PDB:1Y4E}.
FT   HELIX       171    174       {ECO:0000244|PDB:1Y4E}.
FT   HELIX       177    180       {ECO:0000244|PDB:1Y4E}.
FT   HELIX       231    234       {ECO:0000244|PDB:2L0E}.
FT   HELIX       239    249       {ECO:0000244|PDB:2L0E}.
FT   TURN        252    254       {ECO:0000244|PDB:2MDF}.
FT   TURN        256    258       {ECO:0000244|PDB:2MDF}.
FT   HELIX       259    269       {ECO:0000244|PDB:2MDF}.
FT   TURN        271    273       {ECO:0000244|PDB:2MDF}.
FT   HELIX       448    451       {ECO:0000244|PDB:2KBV}.
FT   TURN        452    455       {ECO:0000244|PDB:2KBV}.
FT   HELIX       459    471       {ECO:0000244|PDB:2KBV}.
FT   HELIX       518    538       {ECO:0000244|PDB:2BEC}.
FT   HELIX       625    651       {ECO:0000244|PDB:2YGG}.
FT   HELIX       658    681       {ECO:0000244|PDB:2YGG}.
FT   TURN        682    684       {ECO:0000244|PDB:2YGG}.
SQ   SEQUENCE   815 AA;  90763 MW;  02EC748C79DF6526 CRC64;
     MVLRSGICGL SPHRIFPSLL VVVALVGLLP VLRSHGLQLS PTASTIRSSE PPRERSIGDV
     TTAPPEVTPE SRPVNHSVTD HGMKPRKAFP VLGIDYTHVR TPFEISLWIL LACLMKIGFH
     VIPTISSIVP ESCLLIVVGL LVGGLIKGVG ETPPFLQSDV FFLFLLPPII LDAGYFLPLR
     QFTENLGTIL IFAVVGTLWN AFFLGGLMYA VCLVGGEQIN NIGLLDNLLF GSIISAVDPV
     AVLAVFEEIH INELLHILVF GESLLNDAVT VVLYHLFEEF ANYEHVGIVD IFLGFLSFFV
     VALGGVLVGV VYGVIAAFTS RFTSHIRVIE PLFVFLYSYM AYLSAELFHL SGIMALIASG
     VVMRPYVEAN ISHKSHTTIK YFLKMWSSVS ETLIFIFLGV STVAGSHHWN WTFVISTLLF
     CLIARVLGVL GLTWFINKFR IVKLTPKDQF IIAYGGLRGA IAFSLGYLLD KKHFPMCDLF
     LTAIITVIFF TVFVQGMTIR PLVDLLAVKK KQETKRSINE EIHTQFLDHL LTGIEDICGH
     YGHHHWKDKL NRFNKKYVKK CLIAGERSKE PQLIAFYHKM EMKQAIELVE SGGMGKIPSA
     VSTVSMQNIH PKSLPSERIL PALSKDKEEE IRKILRNNLQ KTRQRLRSYN RHTLVADPYE
     EAWNQMLLRR QKARQLEQKI NNYLTVPAHK LDSPTMSRAR IGSDPLAYEP KEDLPVITID
     PASPQSPESV DLVNEELKGK VLGLSRDPAK VAEEDEDDDG GIMMRSKETS SPGTDDVFTP
     APSDSPSSQR IQRCLSDPGP HPEPGEGEPF FPKGQ
//
